Drotrecogin alfa (activated)

DRUG11 trials

Conditions

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationHypotensionInfectionSepsisSeptic ShockSevere SepsisSubmassive Pulmonary Embolism

Phase 2

Adjuvant Treatment of Pulmonary Embolism With Drotrecogin Alfa (Activated): Phase II Exploratory Study

CompletedNCT00191724

Eli Lilly and CompanySubmassive Pulmonary Embolism

Start: 2004-09-30End: 2008-01-31Updated: 2009-06-24

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

CompletedNCT00386425

Eli Lilly and CompanySevere Sepsis

Start: 2006-11-30End: 2009-08-31Updated: 2010-12-16

Phase 3

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

CompletedNCT00049764

Eli Lilly and CompanySepsis

Start: 2002-11-30End: 2005-04-30Updated: 2007-11-20

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

CompletedNCT00190788

Eli Lilly and CompanyHypotension, Sepsis

Start: 2004-06-30End: 2007-05-31Target: 200Updated: 2007-10-12

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

CompletedNCT00568737

Eli Lilly and CompanySepsis

Start: 2002-11-30End: 2005-02-28Updated: 2007-12-06

Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock

CompletedNCT00604214

Eli Lilly and CompanySepsis

Start: 2008-03-31End: 2012-02-29Updated: 2012-09-18

Phase 4

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

CompletedNCT00045760

Eli Lilly and CompanySepsis

Start: 2002-09-30Updated: 2006-07-20

A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)

CompletedNCT00049777

Eli Lilly and CompanySepsis

Start: 2002-12-31End: 2005-08-31Target: 2000Updated: 2007-01-26

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

CompletedNCT00067730

Eli Lilly and CompanyHematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Infection +1

Start: 2003-03-31End: 2003-10-31Updated: 2007-12-07

Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock

CompletedNCT00279214

Eli Lilly and CompanySepsis, Septic Shock

Start: 2005-11-30End: 2007-11-30Updated: 2009-09-02

An Open Label Study of Severe Sepsis in Adults

CompletedNCT00568893

Eli Lilly and CompanySevere Sepsis

Start: 2003-01-31End: 2003-10-31Updated: 2007-12-06

2015-04-2813 citations

Functional outcomes in pediatric severe sepsis: further analysis of the researching severe sepsis and organ dysfunction in children: a global perspective trial.

2013-11-01115 citations

Drotrecogin alfa (activated) in adults with septic shock.

2012-05-22901 citations

Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism.

2011-01-172 citations

Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).

2010-12-2116 citations

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

2009-05-207 citations

Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

2008-09-118 citations

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

2007-03-01316 citations

Drotrecogin alfa (activated)

Sponsors

Conditions

Phase 2

Phase 3

Phase 4

Related Papers